Characterization of neutralization epitopes in the V2 region of human immunodeficiency virus type 1 gp120: role of glycosylation in the correct folding of the V1/V2 domain.
about
Molecular determinants of species specificity in the coronavirus receptor aminopeptidase N (CD13): influence of N-linked glycosylation.Hepatitis C virus envelope glycoprotein co-evolutionary dynamics during chronic hepatitis CAiming to induce broadly reactive neutralizing antibody responses with HIV-1 vaccine candidatesFunctional and immunochemical cross-reactivity of V2-specific monoclonal antibodies from HIV-1-infected individualsMonoclonal antibodies to conformational epitopes of the surface glycoprotein of caprine arthritis-encephalitis virus: potential application to competitive-inhibition enzyme-linked immunosorbent assay for detecting antibodies in goat seraMonoclonal antibodies to the V2 domain of MN-rgp120: fine mapping of epitopes and inhibition of α4β7 bindingProtease cleavage sites in HIV-1 gp120 recognized by antigen processing enzymes are conserved and located at receptor binding sitesCyanovirin-N binds to gp120 to interfere with CD4-dependent human immunodeficiency virus type 1 virion binding, fusion, and infectivity but does not affect the CD4 binding site on gp120 or soluble CD4-induced conformational changes in gp120.Location-specific, unequal contribution of the N glycans in simian immunodeficiency virus gp120 to viral infectivity and removal of multiple glycans without disturbing infectivityThe C108g epitope in the V2 domain of gp120 functions as a potent neutralization target when introduced into envelope proteins derived from human immunodeficiency virus type 1 primary isolates.Determinants of syncytium formation in microglia by human immunodeficiency virus type 1: role of the V1/V2 domainsConserved and exposed epitopes on intact, native, primary human immunodeficiency virus type 1 virions of group M.Resistance of human immunodeficiency virus type 1 to the high-mannose binding agents cyanovirin N and concanavalin A.Differential CD4/CCR5 utilization, gp120 conformation, and neutralization sensitivity between envelopes from a microglia-adapted human immunodeficiency virus type 1 and its parental isolate.A comparative study of HIV-1 clade C env evolution in a Zambian infant with an infected rhesus macaque during disease progression.Characterization of a monoclonal antibody to a novel glycan-dependent epitope in the V1/V2 domain of the HIV-1 envelope protein, gp120.Molecular evolution of human immunodeficiency virus env in humans and monkeys: similar patterns occur during natural disease progression or rapid virus passage.Glycosylation of the core of the HIV-1 envelope subunit protein gp120 is not required for native trimer formation or viral infectivity.Type-specific epitopes targeted by monoclonal antibodies with exceptionally potent neutralizing activities for selected strains of human immunodeficiency virus type 1 map to a common region of the V2 domain of gp120 and differ only at single positioStructure-function relationships of HIV-1 envelope sequence-variable regions refocus vaccine designRole of V1V2 and other human immunodeficiency virus type 1 envelope domains in resistance to autologous neutralization during clade C infectionSeveral N-Glycans on the HIV Envelope Glycoprotein gp120 Preferentially Locate Near Disulphide Bridges and Are Required for Efficient Infectivity and Virus TransmissionN-butyldeoxynojirimycin-mediated inhibition of human immunodeficiency virus entry correlates with changes in antibody recognition of the V1/V2 region of gp120Improving immunogenicity of HIV-1 envelope gp120 by glycan removal and immune complex formationTargeting a Neutralizing Epitope of HIV Envelope Gp120 by Immune Complex Vaccine.Specific N-linked and O-linked glycosylation modifications in the envelope V1 domain of simian immunodeficiency virus variants that evolve in the host alter recognition by neutralizing antibodies.Comparison of viral Env proteins from acute and chronic infections with subtype C human immunodeficiency virus type 1 identifies differences in glycosylation and CCR5 utilization and suggests a new strategy for immunogen design.Soluble CD4 broadens neutralization of V3-directed monoclonal antibodies and guinea pig vaccine sera against HIV-1 subtype B and C reference viruses.Characterization of structural features and diversity of variable-region determinants of related quaternary epitopes recognized by human and rhesus macaque monoclonal antibodies possessing unusually potent neutralizing activities.Structural modulations of the envelope gp120 glycoprotein of human immunodeficiency virus type 1 upon oligomerization and differential V3 loop epitope exposure of isolates displaying distinct tropism upon virion-soluble receptor binding.The hypervariable domain of the murine leukemia virus surface protein tolerates large insertions and deletions, enabling development of a retroviral particle display system.Antibody-dependent cellular cytotoxicity directed against cells expressing human immunodeficiency virus type 1 envelope of primary or laboratory-adapted strains by human and chimpanzee monoclonal antibodies of different epitope specificities.Selection for neutralization resistance of the simian/human immunodeficiency virus SHIVSF33A variant in vivo by virtue of sequence changes in the extracellular envelope glycoprotein that modify N-linked glycosylation.Role of complex carbohydrates in human immunodeficiency virus type 1 infection and resistance to antibody neutralizationSynergistic neutralization of human immunodeficiency virus type 1 by a chimpanzee monoclonal antibody against the V2 domain of gp120 in combination with monoclonal antibodies against the V3 loop and the CD4-binding siteLocation, exposure, and conservation of neutralizing and nonneutralizing epitopes on human immunodeficiency virus type 2 SU glycoproteinLength polymorphism within the second variable region of the human immunodeficiency virus type 1 envelope glycoprotein affects accessibility of the receptor binding site.The critical N-linked glycan of murine leukemia virus envelope protein promotes both folding of the C-terminal domains of the precursor polyprotein and stability of the postcleavage envelope complexIdentification of the V1 region as a linear neutralizing epitope of the simian immunodeficiency virus SIVmac envelope glycoprotein.Optimization of human immunodeficiency virus type 1 envelope glycoproteins with V1/V2 deleted, using virus evolution.
P2860
Q24529180-2F39F121-9673-42A3-A422-3E363F48B781Q27486537-A77B8F36-1254-4A74-90D4-58C9383FE5D2Q27489000-83FE6B32-C52D-490A-9A50-F20FECB0F5C3Q27677941-52F04E36-F42C-4C08-9EFB-AE0BE7A536B3Q28345448-5A5E2BBD-F487-4545-8E1D-857FE53E115EQ28728517-58EFC45D-05FC-4DDE-ADD7-1611B95D408BQ33614461-32336A52-8129-4335-AA49-495106949543Q33648180-4AF7D89D-ECBC-4DD9-BECF-ECF3F759B094Q33785035-C10CE64B-1C9A-4C33-BE11-A6203B1BCAD7Q33788792-085F5EE4-7461-4C12-B16D-E13C56B85299Q33796067-998A64D6-913C-4D11-BB92-8E270A008D4EQ33809112-5E9BF441-FB25-4789-9602-69FE1FC4C1BBQ33842989-612E5523-84D9-4FFB-8E69-DF069537C218Q33851094-20E9E3BC-5DBA-4DEC-8E73-3341AD35A754Q33980469-9FAD2F75-76D5-4E2E-A0A6-749D67F33E21Q34146374-39A6B694-6407-4115-B452-83B30E4F9330Q34338411-7B876B0E-24C1-4385-98AC-948F6D337169Q34555891-39378604-7025-443E-A419-79039EAF0661Q34583767-FF3A6E63-9518-4A32-9F34-40AE08E0A331Q35196671-9A286E24-A00C-4809-8B03-EF402C3E6FB9Q35635163-A229E0F5-C316-440A-B994-9D96F8AA6F86Q35677448-8CC57CDC-347A-422B-BE1B-5214096A31F2Q35870879-10D496CE-F0D4-4B35-83D6-DE6A2E9C1951Q35893538-0EB6BE8D-CF2E-4076-ABD0-2B80D77E5F85Q36157711-C99275D0-AE35-4159-AAD6-FFDD13CA18E6Q36884458-56E3071E-A6F5-4B71-B06A-D58141F67F9DQ36978861-2A700BCC-A187-4298-B623-16B5C0E0EE09Q37084521-0A08FBE6-089A-434A-AE85-6C39EB8DC73EQ38631979-379EFF9A-40C3-4B72-A34F-803B5BF1CEF7Q39485924-D7E95D05-68FE-458E-AFB3-287502A499CBQ39551618-65194444-8CD4-4283-9D7B-9D5C193EC03FQ39577162-1AB8D65D-C287-4EA2-AE9A-90E8C3E8D651Q39594428-45B7DC5F-FE64-48DD-9523-3FC79E72D4EAQ39723388-7D91710E-19FC-4226-A3E6-B4CC79B87369Q39875133-CE07B197-27B4-4027-92B8-20360FE261A4Q39875204-9ACD75B8-4114-406F-8855-EF822137DCA0Q39877884-1D45E95E-959F-415E-B19F-FF3B1D689358Q39881014-728167D0-8FED-45C6-BE4F-338F281E1D24Q40015450-C0308DD8-6128-4AF9-9708-ED6452A58D3FQ43124783-8F681613-8687-48ED-837A-99BD8876663F
P2860
Characterization of neutralization epitopes in the V2 region of human immunodeficiency virus type 1 gp120: role of glycosylation in the correct folding of the V1/V2 domain.
description
1995 nî lūn-bûn
@nan
1995年の論文
@ja
1995年論文
@yue
1995年論文
@zh-hant
1995年論文
@zh-hk
1995年論文
@zh-mo
1995年論文
@zh-tw
1995年论文
@wuu
1995年论文
@zh
1995年论文
@zh-cn
name
Characterization of neutraliza ...... t folding of the V1/V2 domain.
@en
Characterization of neutraliza ...... t folding of the V1/V2 domain.
@nl
type
label
Characterization of neutraliza ...... t folding of the V1/V2 domain.
@en
Characterization of neutraliza ...... t folding of the V1/V2 domain.
@nl
prefLabel
Characterization of neutraliza ...... t folding of the V1/V2 domain.
@en
Characterization of neutraliza ...... t folding of the V1/V2 domain.
@nl
P2093
P2860
P1433
P1476
Characterization of neutraliza ...... ct folding of the V1/V2 domain
@en
P2093
J McKeating
S A Tilley
S C Kayman
S Vijh-Warrier
P2860
P304
P407
P577
1995-04-01T00:00:00Z